NCT00428974 - Safety and Efficacy Study of CF101 to Treat Psoriasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions

Plaque Psoriasis

Interventions

DRUG

CF101 1mg

CF101 1 mg q12 hours for 12 weeks

DRUG

CF101 2mg

CF101 2 mg q12 hours for 12 weeks

DRUG

CF101 4mg

CF101 4 mg q12 hours for 12 weeks

DRUG

Placebo

Placebo tablets q12 hours for 12 weeks

Trial Locations (4)

Haemek Medical Center, Afula

Wolfson Medical Center, Holon

Rabin Medical Center, Petah Tikva

Sheba Medical Center, Tel Litwinsky